Badilla MJ, Cambronero AN

Idioma: Español
Referencias bibliográficas: 19
Paginas: 485-489
Archivo PDF: 540.70 Kb.

RESUMEN

El carcinoma diferenciado de tiroides metastatiza fundamentalmente en pulmón y hueso, y con menos frecuencia en cerebro, hígado y piel. Se describe las características clínicas, terapéuticas e histológicas del tumor primario en un caso de metástasis de carcinoma diferenciado de tiroides en lugares poco habituales. El caso se trata de un carcinoma papilar, que presentó una metástasis en glándula suprarrenal derecha. En conclusión, ante un carcinoma diferenciado de tiroides, es posible encontrar metástasis en los lugares habituales y también en otros más infrecuentes. Determinadas variedades del carcinoma papilar de tiroides como es la de células altas, presentan un comportamiento especialmente agresivo y pueden metastatizar en lugares poco habituales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. AACE clinical practice guidelines for the management of thyroid carcinoma. Endocr Pract 1997; 3: 60-71.

2. Bellantone R, Lombardi CP, Boscherini M, et al. Prognostic factors in differentiated thyroid carcinoma: a multyvariate analysis of 234 consecutive patients. J Surg Oncol 1998; 68: 237-41.

3. Burns D. Carcinoma tiroideo. En:Cotran RS, Kumar V, Collins. Patología estructural y funcional. 6 ed. Barcelona:Interamericana de España, 1999:1174-92.

4. De Groot LJ, Kaplan EL, McKormick M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-24.

5. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995; 80: 2041-5.

6. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-8.

7. Hoie J, Stenwig AE, Kullman G, Lindegaard M. Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer 1988; 61: 1-6.

8. Kelemen PR, Van Herle AJ, Giuliano AE. Sentinel lymphadenectomy in thyroid malignant neoplasms. Arch Surg 1998; 133: 288-92.

9. Mann B, Burh HJ. Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits? Langenbecks Arch Surg 1998; 383:355-8.

10. McDougall IR. Whole-Body Scintigraphy with Radioiodine-131. A comprehensive list of false positives with some examples. Clin Nucl Med 1995; 20: 869-75.

11. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer incidence in five continents. International Agency for Research on cancer. Lyon, France 1992; 120 (6).

12. Sabders LE, Cady B. Differentiated thyroid cancer: reexamination of risk group and outcome of treatment. Arch Surg 1999;133(4):419-25.

13. Sato N, Oyamatsu M, Koyama Y, EmuraI, Tamiysa I, Hatakeyama K. Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland?. J Surg Oncol 1998; 69: 151-5.

14. Schlumberger M, Challeton C, De Vathaire F, et al. Radioctive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37: 598-605.

15. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Eng J Med 1998; 338: 297-307.

16. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997; 174: 474-6.

17. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 156: 2165-72.

18. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocri nol Metab 1996; 81: 333-9.

19. Sorge-Van Boxel RAJ, Van Eck-Smit BLF, Goslings BM. Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the postoperative follow-up differentiated thyroid cancer. Nucl Med Comm 1993; 14: 365.